Cardiovasc cardiovasc.com


Public lists: Pharma Startups (4732)

Cardiovasc is a cardiovascular research group that explores the cellular mechanisms responsible for major cardiovascular and metabolic diseases and to identify new cellular targets for drug therapys to help protect the cardiovascular system.

Cardiovasc is a cardiovascular research group that explores the cellular mechanisms responsible for major cardiovascular and metabolic diseases and to identify new cellular targets for drug therapys to help protect the cardiovascular system.

Company (Alive / Active)

All investors data 1 Investors

Phone:

Fax:

Department of Biochemistry, University of Szeged
D0m ter 9
H-6720
Hungary

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cardiovasc $0M Nov 29, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cardiovasc Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Xenon Pharmaceuticals

Burnaby, British Columbia, Canada
IPO / Went publicXenon Pharmaceuticals is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. The company has built a core platform, Extreme Genetics, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mut...Show allLogin to see details

Echelon Biosciences

Salt Lake City, Utah, United States
Alive / ActiveEchelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brai...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)